ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
化工社オープンプロジェクト：[email protected]AIアクセス：llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.7.8
戻る
化工社化工社 化学情報印刷レポート · 研究参考用
HCID 2707作成日：2026年10月27日

抱水クロラール

抱水クロラール · クロラール水和物 · 2,2,2-トリクロロ-1,1-エタンジオール · 2,2,2-トリクロロ-1,1-エタン-ジオール · 2,2,2-トリクロロエタン-1,1-ジオール · エスクレ · 抱水クロラ-ル · トリクロロアセトアルデヒド一水和物

https://huagongshe.com/ja/chemical/2707

抱水クロラール の分子構造式

識別子と物理属性

CAS No.302-17-0
分子式C2H3Cl3O2
平均分子量165.4 g/mol
単同位体質量163.91986238 g/mol
SMILESOC(O)C(Cl)(Cl)Cl
InChIKeyRNFNDJAIBTYOQL-UHFFFAOYSA-N
PubChem CID2707
ChEMBLCHEMBL455917
ChEBICHEBI:28142
EC No.206-117-5
DTXSIDDTXSID7020261
現地名抱水クロラール

化学・物理的性質

XLogP1
極性表面積40.5
水素結合供与体数2
水素結合受容体数2
回転可能結合数0
重原子数7
形式電荷0
複雑度56.4
物質分類Other Classes -> Halogenated AlcoholsCarcinogens
医薬品DEA NFLIS-Drug Category -> Depressants and TranquilizersDEA Schedule IV Controlled Substance -> DepressantsPharmaceuticals -> AntiepilepticsPharmaceuticals -> Listed in ZINC15Pharmaceuticals -> Used in Switzerland
pH3.5-4.4 (10% soln in water)3.5-5.5 (20℃, 10%)
SpringerMaterials PropertiesMoessbauer quadrupole effect
農薬Pesticide -> EPA IRIS
LogP（分配係数）log Kow = 0.99
臭いAromatic, penetrating and slightly acrid odorCharacteristic: sweet
味Slightly bitter, caustic taste
密度1.9081 at 68 °F (NTP, 1992) - Denser than waterwill sink1.9081 g/cu cm at 20 °C/4 °C1.9 g/cm³1.9081 @ 20°C1.43 g/mL at 20 °C
Color/FormCOLORLESS OR WHITE CRYSTALSTransparent, colorless crystalsLarge, monoclinic plates
溶解度greater than or equal to 10 mg/mL at 68.9 °F (NTP, 1992)Freely soluble in acetone, methyl ethyl ketone. Moderately or sparingly soluble in turpentine, petroleum ether, carbon tetrachloride, benzene, toluene.Very soluble in benzene, ethyl ether, and ethanol.In water, 7.93X10+5 mg/L at 25 °CSolubility in water: very good水に非常に溶けやすく、エタノールに溶けやすい (96%)。660g/100mL
Corrosivity... Corrosive to the skin and mucous membrane unless well diluted
融点57 °C(lit.)
沸点97 °C
蒸気圧19.998hPa at 25℃
屈折率1.4603 (estimate)
引火点16 °C
貯蔵条件0-6°C
pKa（酸解離定数）10(at 25℃)
外観・状態A crystalline solid
比重1.91
Merck13,2080
BRN1698497
ヘンリー定数2.4×103 mol/(m3Pa) at 25℃, HSDB (2015)
誘電率5.5(15℃)
安定性安定していますが、空気や光に敏感な場合があります。アルコール、シアン化物、ヨウ素、強塩基、炭酸塩とは相容れない。
主な用途環境
InChI1S/C2H3Cl3O2/c3-2(4,5)1(6)7/h1,6-7H
InChIKeyRNFNDJAIBTYOQL-UHFFFAOYSA-N
SMILESOC(O)C(Cl)(Cl)Cl
LogP（分配係数）1.092 at 25℃
CAS データベース302-17-0(CAS DataBase Reference)
NISTの化学物質情報Chloral hydrate(302-17-0)
EPAの化学物質情報Chloral hydrate (302-17-0)

安全性と法規制

GHS 分類DangerH301: Toxic if swallowed [Danger Acute toxicity, oral]P264, P264+P265, P270, P280, P301+P316, P302+P352, P305+P351+P338, P321, P330, P332+P317, P337+P317, P362+P364, P405, and P501 (click each P-code to see the statement)H301 (99%): Toxic if swallowed [Danger Acute toxicity, oral]
規制情報Chemical: 1,1-Ethanediol, 2,2,2-trichloro-Hazard Traits - CarcinogenicityNeurotoxicityDEA schedule IV controlled substanceStatus: Active Update: 01-03-2023 https://echa.europa.eu/registration-dossier/-/registered-dossier/17704Chloral hydrate: Does not have an individual approval but may be used under an appropriate group standardThe New Jersey Worker and Community Right to Know Act requires public and private employers to provide information about hazardous substances at their workplaces. (N.J.S.A. 34:5A-1 et. seq.)
輸送ラベル（DOT）Poison
火災危険Flash point data for this chemical are not availablehowever, it is probably combustible. (NTP, 1992)Not combustible. Gives off irritating or toxic fumes (or gases) in a fire.
火災の可能性Combustible when exposed to heat or flame.
健康有害性SYMPTOMS: Symptoms of exposure to this compound include general anesthesia, cardiac arrythmias and blood pressure depression. Other symptoms include hemorrhagic gastritis, enteritis, central nervous system depression, coma, severe respiratory depression, ventricular tachycardia and cardiac arrest. Dermatitis, swelling of the lids, hyperemia, edema of the conjuctiva and a sensation of irritation and tearing may also occur. Exposure may result in gastric irritation, rapid circulatory collapse, kidney and liver damage, heart damage, psychosis and leukopenia. Flatulence, abdominal distension, nausea, headache, giddiness, rashes and blood dyscrasias can occur.
有害性の概要A skin, eye, and respiratory tract irritantA CNS depressant[ICSC] A skin and mucous membrane irritantMay cause eye injury[HSDB] A skin and eye irritant[eChemPortal: ERMAESIS] An irritant

用途

用途

睡眠?抗痙攣剤(有機化合物辞典(1985))GLUE PEPTIZING AGENT; MEDICINE (SEDATIVE), MANUFACTURE OF DDT, LINAMENTS. ; MANUFACTURE OF DICHLOROACETIC ACID IN THE LABORATORY.(HSDB(2010))

説明

Chloral hydrate is one of the oldest sedatives used for dental sedation. It was first synthesized in 1832 by Justus von Liebig and was the first synthetic central nervous system (CNS) depressant. It was used to treat delirium tremens, insomnia, and anxiety, although it is considered an unapproved drug by the US Food and Drug Administration. Initially considered to be a safer alternative to opium, it was noted to produce rapid unconsciousness when combined with ethanol. Physical dependence can occur with chronic use.Chloral hydrate is classified as a sedative-hypnotic and is known to induce sleep in children. It has been very popular in pediatric dentistry since the mid-1950s. Chloral hydrate is rapidly absorbed following oral administration and is converted through its first pass in the liver to trichloroethanol，its active form. Trichloroethanol is conjugated in the liver and excreted in the urine. Like other agents that are metabolized in the liver, chloral hydrate may interact with other drugs, herbs, or foods resulting in clinically significant alterations of the agents (e.g.,warfarin).

使用

Trichloroacetaldehyde Hydrate is a useful chemical reagent used as a sedative/hypnotic agent for the short-term treatment of insomnia. First developed in 1832, chloral hydrate is the oldest sleep medication still in use today. This medication is also used to calm you just before surgery or other procedures. It works by affecting certain parts of the brain to cause calmness. Studies have shown that when used in pediatric sedation side effects such as hallucination, excessive sleep and seizures were observed. Drowsiness and trouble waking up in the morning, nausea, vomiting, stomach pain, diarrhea, and headache may occur. Stomach problems can be reduced by taking chloral hydrate with a full glass of water. It is sometimes administered to patients being treated with cyclophosphamide and it is known to inhibit some aldehyde dehydrogenases. Besides, Chloral hydrate is a starting point for the synthesis of other organic compounds. It is the starting material for the production of chloral, which is produced by the distillation of a mixture of chloral hydrate and sulfuric acid, which serves as the desiccant.

一般的な説明

Chloral hydrate, trichloroacetaldehydemonohydrate, CCl3CH(OH)2 (Noctec), is analdehyde hydrate stable enough to be isolated. The relativestability of this gem-diol is largely a result of an unfavorabledipole–dipole repulsion between the trichloromethyl carbonand the carbonyl carbon present in the parent carbonylcompound.Chloral hydrate is unstable in alkaline solutions, undergoingthe last step of the haloform reaction to yield chloroformand formate ion. In hydroalcoholic solutions, it formsthe hemiacetal with ethanol. Whether or not this compoundis the basis for the notorious and potentially lethal effect of the combination of ethanol and chloral hydrate (the “MickeyFinn”) is controversial. Synergism between two differentCNS depressants also could be involved. Additionally,ethanol, by increasing the concentration of nicotinamideadenine dinucleotide (NADH), enhances the reduction ofchloral to the more active metabolite trichloroethanol, andchloral can inhibit the metabolism of alcohol because it inhibitsalcohol dehydrogenase. Chloral hydrate is a weak acidbecause its CCl3 group is very strong electron withdrawing.A 10% aqueous solution of chloral hydrate has pH 3.5 to4.4, which makes it irritating to mucous membranes in thestomach. As a result, GI upset commonly occurs for thedrug if undiluted or taken on an empty stomach. Chloral hydrateas a capsule, syrup, or suppository is currently available.

[MSDSonline] Liver injury reported after lethal doses, but not after therapeutic doses
[INCHEM: CICADS]
FDA 要件Drug products containing certain active ingredients offered over-the-counter (OTC) for certain uses. A number of active ingredients have been present in OTC drug products for various uses, as described below. However, based on evidence currently available, there are inadequate data to establish general recognition of the safety and effectiveness of these ingredients for the specified uses: chloral hydrate is included in external analgesic drug products - analgesic and anesthetic drug products.Drug products containing certain active ingredients offered over-the-counter (OTC) for certain uses. A number of active ingredients have been present in OTC drug products for various uses, as described below. However, based on evidence currently available, there are inadequate data to establish general recognition of the safety and effectiveness of these ingredients for the specified uses: chloral hydrate is included in external analgesic drug products - counter irritant drug products.Drug products containing certain active ingredients offered over-the-counter (OTC) for certain uses. A number of active ingredients have been present in OTC drug products for various uses, as described below. However, based on evidence currently available, there are inadequate data to establish general recognition of the safety and effectiveness of these ingredients for the specified uses: chloral hydrate is included in external analgesic drug products - fever blister and cold sore treatment drug products.Drug products containing certain active ingredients offered over-the-counter (OTC) for certain uses. A number of active ingredients have been present in OTC drug products for various uses, as described below. However, based on evidence currently available, there are inadequate data to establish general recognition of the safety and effectiveness of these ingredients for the specified uses: chloral hydrate is included in external analgesic drug products - poison ivy, poison oak, and poison sumac drug products.For more FDA Requirements (Complete) data for CHLORAL HYDRATE (8 total), please visit the HSDB record page.
反応性グループAlcohols and Polyols
EC 分類Symbol: TR: 25-36/38S: (1/2)-25-45
UN 分類UN Hazard Class: 6.1
Special ReportsDHHS/NIDAResearch Monograph Series 52: Testing Drugs for Physical Dependence Potential and Abuse Liability (1984) DHHS Pub No. (ADM)87-1332Research Monograph Series 54: Mechanisms of Tolerance and Dependence (1984) DHHS Pub No. (ADM)88-1330Research Monograph Series 56: Etiology of Drug Abuse: Implications for Prevention (1987) DHHS Pub No. (ADM)87-1335Research Monograph Series 59: Current Research on the Consequences of Maternal Drug Abuse (1985) DHHS Pub No. (ADM)85-1400For more Special Reports (Complete) data for CHLORAL HYDRATE (9 total), please visit the HSDB record page.
Reactivity ProfileCHLORAL HYDRATE is incompatible with alkalis, alkaline earth metals, alkali carbonates and soluble barbiturates. It is decomposed by sodium hydroxide. It reduces ammoniacal silver nitrate. It liquefies when triturated with an equal quantity of menthol, camphor or thymol. (NTP, 1992). Reaction of chloral hydrate with hydroxylamine produces toxic hydrogen cyanide gas, Org. Synth., 1941, Vol. 1, 377.
消火Fires involving this material can be controlled with a dry chemical, carbon dioxide or Halon extinguisher. (NTP, 1992)In case of fire in the surroundings, use appropriate extinguishing media. In case of fire: keep drums, etc., cool by spraying with water.
応急処置措置Fresh air, rest. Artificial respiration may be needed. Refer immediately for medical attention.Rinse skin with plenty of water or shower.First rinse with plenty of water for several minutes (remove contact lenses if easily possible), then refer for medical attention.Rinse mouth. Do NOT induce vomiting. Refer immediately for medical attention.
応急処置EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.
安全保管Separated from strong bases and food and feedstuffs.
保管条件Chloral hydrate oral solution should be stored in tight, light-resistant containers. Chloral hydrate capsules should be stored at 15-30 °C.
非火災時の漏出対応SMALL SPILLS AND LEAKAGE: If you spill this chemical, you should dampen the solid spill material with water, then transfer the dampened material to a suitable container. Use absorbent paper dampened with water to pick up any remaining material. Seal your contaminated clothing and the absorbent paper in a vapor-tight plastic bag for eventual disposal. Wash all contaminated surfaces with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.
処分方法SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.Chloral hydrate is a waste chemical stream constituent which may be subjected to ultimate disposal by controlled incineration. Preferably after mixing with another combustible fuel, care must be exercised to assure complete combustion to prevent the formation of phosgenean acid scrubber is necessary to remove the halo acids produced.The following wastewater treatment technology has been investigated for chloral hydrate: Concentration process: Solvent extraction.
漏出処分Personal protection: particulate filter respirator adapted to the airborne concentration of the substance. Sweep spilled substance into covered containers. If appropriate, moisten first to prevent dusting. Carefully collect remainder. Then store and dispose of according to local regulations.
Preventive MeasuresSRP: The scientific literature for the use of contact lenses in industry is conflicting. The benefit or detrimental effects of wearing contact lenses depend not only upon the substance, but also on factors including the form of the substance, characteristics and duration of the exposure, the uses of other eye protection equipment, and the hygiene of the lenses. However, there may be individual substances whose irritating or corrosive properties are such that the wearing of contact lenses would be harmful to the eye. In those specific cases, contact lenses should not be worn. In any event, the usual eye protection equipment should be worn even when contact lenses are in place.
Isolation and EvacuationExcerpt from ERG Guide 154 [Substances - Toxic and/or Corrosive (Non-Combustible)]:
Eye PreventionWear safety spectacles or eye protection in combination with breathing protection if powder.
Inhalation RiskA harmful contamination of the air will be reached rather slowly on evaporation of this substance at 20 °C.
体内負荷Chloral hydrate has been detected in /human/ ... milk ... .Chloral hydrate and its metabolite, trichloroethanol reached 50-100% /in breast milk/ of maternal blood levels in most of 50 women given 1.3 g rectally.
相互作用Prolonged concurrent use /with other addictive medications especially CNS depressants with habituating potential/ may increase the risk of habituationcaution is recommended.Concurrent use /with alcohol or other CNS depression-producing medications/ may increase the CNS depressant effect of either these medications or chloral hydratecaution is recommended and dosage of one or both agents should be reduced.Hypoprothrombinemic effects may be increased when these medications /coumarin- or indandione-derivative anticoagulants/ are used concurrently with chloral hydrate, particularly during the first 2 weeks of concurrent therapy, because of displacement of the anticoagulant from its plasma protein binding siteswith continued concurrent use, anticoagulant activity may return to baseline level or be decreasedfrequent prothrombin-time determinations may be required, especially during initiation of chloral hydrate therapy, to determine if dosage adjustment of the anticoagulant is necessary.Administration of chloral hydrate followed by intravenous furosemide within 24 hours may result in diaphoresis, hot flashes, and variable blood pressure, including hypertension, due to a hypermetabolic state caused by displacement of thyroxine from its bound state.For more Interactions (Complete) data for CHLORAL HYDRATE (13 total), please visit the HSDB record page.
標的器官Gastrointestinal
HepatotoxicityChloral hydrate has been in clinical use for many decades and has not been linked to serum enzyme elevations during therapy or instances of clinically apparent liver injury. While prospective studies of the effects of chloral hydrate on liver tests have not been done, the absence of reported instances of liver injury attributable to chloral hydrate suggests that it has little or no hepatic toxicity. Chloral hydrate has been linked to hypersensitivity reactions such as rash, fever and eosinophilia. Chloral hydrate also has major drug-drug interactions with oral anticoagulants, antidepressants and alcohol. In patients with cirrhosis and hepatic decompensation, chloral hydrate can trigger or worsen hepatic encephalopathy.
生態毒性値EC50Species: Daphnia magna (Water flea)Conditions: freshwaterpH 8Concentration: 630 mg/L for 24 hrEffect: behavior, equilibrium /Conditions of bioassay not specified in source examined/Concentration: 500 mg/L for 48 hrEffect: intoxication, immobilization /Conditions of bioassay not specified in source examined/LC50Species: Daphnia magna (Water flea, age < or =24 hr)static, 20-22 °C, pH 7.6-7.7Concentration: 510 mg/L for 24 hrSpecies: Leuciscus idus melanotus (Carp)Concentration: 1720 mg/L for 48 hr /Conditions of bioassay not specified in source examined/
環境中動態TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 82(SRC), determined from a log Kow of 0.99(2) and a regression-derived equation(3), indicates that chloral hydrate is expected to have high mobility in soil(SRC). Volatilization of chloral hydrate from moist soil surfaces is expected to be an important fate process(SRC) given an estimated Henry's Law constant of 5.7X10-9 atm-cu m/mole(SRC) derived from its vapor pressure, 15 mm Hg(4), and water solubility, 7.93X10+5 mg/L(5). Chloral hydrate is expected to volatilize from dry soil surfaces(SRC) based upon its vapor pressure(4). Biodegradation data for chloral hydrate were not available(5).AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 82(SRC), determined from a log Kow of 0.99(2) and a regression-derived equation(3), indicates that chloral hydrate is not expected to adsorb to suspended solids and sediment(SRC). Volatilization from water surfaces is expected(3) based upon an estimated Henry's Law constant of 4.1X10-9 atm-cu m/mole(SRC), derived from its vapor pressure, 15 mm Hg(4), and water solubility, 7.93X10+5 mg/L(5). Using this Henry's Law constant and an estimation method(3), volatilization half-lives for a model river and model lake are 12 days and 88 days, respectively(SRC). According to a classification scheme(6), an estimated BCF of 3(SRC), from its log Kow(2) and a regression-derived equation(7), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Biodegradation data for chloral hydrate were not available(8).ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), chloral hydrate, which has a vapor pressure of 15 mm Hg at 25 deg(2), is expected to exist solely as a vapor in the ambient atmosphere. Vapor-phase chloral hydrate is degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals(SRC)the half-life for this reaction in air is estimated to be 8 days(SRC), calculated from its rate constant of 1.9X10-12 cu cm/molecule-sec at 25 °C(SRC) that was derived using a structure estimation method(3). The related aldehyde chloral is readily photolyzed in sunlight based on an atmospheric half-life of 4.5-6 hours for this compound under conditions representing the solar flux during summer months(4).
有害作用Neurotoxin - Acute solvent syndrome
暴露経路The substance can be absorbed into the body by inhalation of its vapour or dust and by ingestion.
Milk ConcentrationsChloral hydrate has been detected in /human/ ... milk ... .Chloral hydrate and its metabolite, trichloroethanol reached 50-100% /in breast milk/ of maternal blood levels in most of 50 women given 1.3 g rectally. Drug and metabolites were detectable for up to 24 hrthe maximum dose that an infant could have received approximates a sedative dose. In another study, drowsiness was noted in 1 infant the morning after a bedtime hypnotic dose of a chloral hydrate derivative in the mother.Following therapeutic doses of chloral hydrate, only small, clinically insignificant amt of the active metabolite are distributed into milk.
毒性の概要IDENTIFICATION: Chloral hydrate is used in human and veterinary medicine as a sedative and hypnotic drug. HUMAN EXPOSURE: The major route of exposure of the general public is from drinking water, as chloral hydrate is formed when drinking water is disinfected with chlorine. Since chloral hydrate is a metabolite of trichloroethylene and tetrachloroethylene, people will be exposed to chloral hydrate if they are exposed to these chemicals. The public will be exposed to the metabolites of chloral hydrate, trichloroacetic acid and dichloroacetic acid, as these chemicals are also formed when drinking water is disinfected with chlorine. In its use as a sedative for people, the metabolite trichloroethanol is responsible for the pharmacologic effect. No quantitative information is available from occupational exposure. Chloral hydrate is irritating to the skin and mucous membranes and often causes gastric distress, nausea and vomiting at the recommended clinical dose. An overdose of this drug produces (in order of progression) ataxia, lethargy, deep coma, respiratory depression, hypotension and cardiac arrhythmia. There is some evidence of hepatic injury in people surviving near lethal acute overdoses. Despite its long use in human medicine there is no published information on toxicity in controlled studies in humans following extended exposure. Chloral hydrate is completely absorbed and rapidly metabolized following oral admin. In humans the half-life of trichloroethanol and its glucuronide is about 8 hrthe half-life of trichloroacetic acid is about 4 days. Some data suggest that half-life of trichloroethanol is incr several fold in pre-term and full term infants compared with toddlers and adults. The major routes of excretion of the metabolites of chloral hydrate is elimination in the urine.Chloral hydrate and its metabolites have been found in milk from women treated with this drug. There no carcinogenicity data from humans. ANIMAL STUDIES: Acute administration of chloral hydrate to mice causes loss of coordination (ataxia). A 90 day study in mice shows no evidence of behavioral changes or other neurotoxicity. Chronic studies in rats and mice show no evidence of behavioral changes and no evidence of histopathological changes in the nervous tissue. A slight detriment in humoral immunity was observed following exposure of mice for 90 days. This drug has been tested for developmental effects in rats and mice. No structural abnormalities were observed. In a neurodevelopmental study in mice, there was a slight effect in passive avoidance learning. Two bioassays in rats show no incr in tumors at any site. Three separate bioassays in male mice showed an incr incidence of liver tumors. The most definitive of these studies shows an incr incidence and multiplicity of liver tumors at each of three exposures. These data show suggestive evidence of carcinogenicity in male mice but are not considered appropriate for conducting a human health risk assessment with a linear response at low exposure. A variety of results show that chloral hydrate is a weak gene mutagen and clastogen. Chloral hydrate induces aneuploidy in a wide variety of cell types.
Signs and SymptomsCough. Confusion. Drowsiness. Nausea. Unconsciousness.Redness.Abdominal pain. Vomiting. Further see Inhalation.
Ongoing Test StatusThe following link will take the user to the National Toxicology Program (NTP) Test Agent Search Results page, which tabulates all of the "Standard Toxicology & Carcinogenesis Studies", "Developmental Studies", and "Genetic Toxicity Studies" performed with this chemical. Clicking on the "Testing Status" link will take the user to the status (i.e., in review, in progress, in preparation, on test, completed, etc.) and results of all the studies that the NTP has done on this chemical. [http://ntp-apps.niehs.nih.gov/ntp_tox/index.cfm?fuseaction=ntpsearch.searchresults&searchterm=302-17-0]
州飲料水ガイドライン(ME) MAINE 70 ug/l
連邦飲料水ガイドラインEPA 60 ug/l
水環境危害等級（WGK）2
TSCA 収載状態TSCA listed
RTECS 番号FM8750000
輸送番号（UN）UN 3286 3/PG 2
毒性LD50 oral in rat: 479mg/kg
税関コード29055900
危険文句（R）25-36/38-39/23/24/25-23/24/25-11-36/37/38-36-20/21/22
化審法(2)-528
安衛法57,57-2
消防法危-4-1-II
危険表示T,F,Xn
安全措置（S）26-45-25-23-36/37-16-27
危険等級6.1(b)Acute Tox. 4 DermalAcute Tox. 4 InhalationAcute Tox. 4 OralEye Irrit. 2
包装等級III
環境リスク評価2,2,2-トリクロロエタン-1,1-ジオール(302-17-0)
貯蔵分類3 - Flammable liquids
有害物質データ302-17-0(Hazardous Substances Data)